U.S. License Holder:
Eli Lilly and Co.
Date of License:
TALTZ (ixekizumab) is a humanized interleukin-17A antagonist indicated for the treatment of:
Patients aged 6 years or older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy;
Adults with active psoriatic arthritis;
Adults with active ankylosing spondylitis;
Adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation.
Inter Partes Review ProceedingsPTAB Portal
IPR Case No(s):
U.S. Patent No.
10,011,654 (Antibodies Directed to IL-17A/IL-17F)
Eli Lilly & Co.
§ 102 Challenge
Claim Types Challenged Under § 102
Composition of Matter Formulation
§ 102 Challenge Instituted
§ 103 challenge
Final Written Decision Issued
Challenges Also Include Written Description and Enablement. Termination / Final Written Decision- Patent Owner Request for Adverse Judgment